Table III.
Clinical and molecular characteristics of ASXL1-mutant patients with essential thrombocythemia.
| Patient ID | Age (years) | Sex | ASXL1 mutant type | Characteristic mutations | FU (months) | OS (months) | Survival status |
|---|---|---|---|---|---|---|---|
| P1 | 66 | M | G652S | CALR positive | 20 | 20 | Alive |
| P2 | 20 | M | G652S | TN | 29 | 29 | Alive |
| P3 | 54 | F | G652S | CALR positive | 23 | 23 | Alive |
| P4 | 51 | F | G652S | CALR positive | 24 | 24 | Alive |
| P5 | 44 | M | G652S | TN | 37 | 37 | Alive |
| P6 | 59 | F | G652S | TN | 15 | 15 | Alive |
| P7 | 58 | F | G652S | CALR positive | 23 | 23 | Alive |
| P8 | 41 | M | G652S | CALR positive | 19 | 19 | Alive |
| P9 | 10 | M | G652S | JAK2V617F positive | 35 | 35 | Alive |
| P10 | 65 | M | G652S | JAK2V617F positive | 39 | 39 | Alive |
| P11 | 60 | M | G652S | JAK2V617F positive | 103 | 103 | Alive |
| P12 | 73 | F | G652S | JAK2V617F positive | 63 | 63 | Alive |
| P13 | 58 | F | G652S | TN | 150 | 150 | Alive |
| P14 | 56 | F | G652S | JAK2V617F positive | 25 | 25 | Alive |
TN, triple-negative; JAK, Janus kinase; CALR, calreticulin; ASXL1, additional sex combs like 1; M, male; F, female; FU, follow-up time; OS, overall survival; MPL, myeloproliferative leukemia.